Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bioequivalence of Ruxolitinib XR Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants

NCT06555081 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06555081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06555081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bioequivalence of Ruxolitinib XR Tablets With Ruxolitinib IR Tablets Administered Orally in Healthy Participants
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Completed
Start date
September 25, 2024
Completion date
November 7, 2024
Enrollment
168 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants